Drug intelligence / Profile preview

hPV19

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hPV19 is a monoclonal antibody (mAb) that targets vascular endothelial growth factor (VEGF). It binds to human VEGF at a unique binding site, inhibiting the activity of VEGF. This mechanism is intended to block angiogenesis, the process by which new blood vessels form from pre-existing vessels, which is critical for tumor growth and metastasis. hPV19 is being investigated as an anti-angiogenic therapy in oncology settings[1].

Brand names: Affecizx
Other names: anti-VEGF monoclonal antibody hPV19

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on hPV19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hPV19.

Explore the full profile